UAE Healthcare Breaks Ground with Historic Surgeries and Future-Ready Innovations in 2025
The UAE's healthcare sector is cementing its global leadership in 2025 through a string of landmark procedures and groundbreaking innovations across critical specialties.
From historic surgeries to futuristic tech, the nation's medical institutions are redefining excellence. Kings College Hospital London Dubai recently performed the city's first liver transplant on a 13-month-old child, born with biliary atresia and a congenital heart defect. The complex case, supported by Al Jalila Foundation, highlights the depth of pediatric expertise now available locally.
Cleveland Clinic Abu Dhabi made global headlines with the world's first remotely performed robotic-assisted focal therapy for prostate cancer. Using the Focal-One system, the procedure eliminated the need for invasive surgery. The hospital also carried out the UAE's first simultaneous robotic kidney transplant for donor and recipient using a single robot.
Women's health saw a leap forward at Corniche Hospital with a minimally invasive egg collection and freezing procedure, offering a new frontier in fertility care. In regenerative medicine, the Abu Dhabi Stem Cells Centre reported promising results for Type 1 diabetes treatment using umbilical cord-derived stem cells.
Major strides were also revealed at Arab Health 2025, where Emirates Health Services introduced two ambitious projects: artificial heart transplantation and pancreatic cell transplantation. Meanwhile, a clinical trial in Abu Dhabi on StromaForte for knee osteoarthritis showed strong potential in cell-based therapy.
Looking ahead, M42 will bring heavy ion therapy—among the most advanced cancer treatments—to Cleveland Clinic Abu Dhabi. The hospital also launched a BioButton-powered remote monitoring programme for cancer patients during Abu Dhabi Global Healthcare Week, underscoring the UAE's commitment to personalized, tech-driven care.
With AI, robotics, and precision medicine at the forefront, the UAE continues to reshape the future of global healthcare.
News Source: Emirates News Agency
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Channel Post MEA
6 hours ago
- Channel Post MEA
Snowflake Introduces New Product Innovations For Data And AI
Snowflake has announced several product innovations at its annual user conference, Snowflake Summit 2025, designed to revolutionize how enterprises manage, analyze, and activate their data in the AI era. These announcements span data engineering, compute performance, analytics, and agentic AI capabilities, all aimed at helping organizations break down data silos and bridge the gap between enterprise data and business action — without sacrificing control, simplicity, or governance. 'With our latest announcements, we're showcasing how Snowflake is fundamentally redefining what organizations can expect from a modern data platform,' said James Petter, Vice President, Snowflake EMEA. 'These innovations are focused on helping businesses make AI and machine learning workflows more easy, connected, and trusted for users of all abilities by democratizing access to data and eliminating the technical overhead that slows down business decision-making.' Snowflake Openflow Unlocks Full Data Interoperability, Accelerating Data Movement for AI Innovation Snowflake unveiled Snowflake Openflow, a multi-modal data ingestion service that allows users to connect to virtually any data source and drive value from any data architecture. Now generally available on AWS, Openflow eliminates fragmented data stacks and manual labor by unifying various types of data and formats, enabling customers to rapidly deploy AI-powered innovations. Snowflake Openflow embraces open standards, so organizations can bring data integrations into a single, unified platform without vendor lock-in and with full support for architecture interoperability. Powered by Apache NiFi, an Apache Software Foundation project built to automate the flow of data between systems, Snowflake Openflow enables data engineers to build custom connectors in minutes and run them seamlessly on Snowflake's managed platform. With Snowflake Openflow, users can harness their data across the entire end-to-end data lifecycle, while adapting to evolving data standards and business demands. Hundreds of ready-to-use connectors and processors simplify and rapidly accelerate data integration from a broad range of data sources including Box, Google Ads, Proofpoint, ServiceNow, Workday, Zendesk, and more, to a wide array of destinations including cloud object stores and messaging platforms, not just Snowflake. Snowflake Unveils Next Wave of Compute Innovations For Faster, More Efficient Warehouses and AI-Driven Data Governance Snowflake announced the next evolution of compute innovations that deliver faster performance, enhanced usability, and stronger price-performance value — raising the bar for modern data infrastructure. This includes Standard Warehouse – Generation 2 (Gen2) (now generally available), an enhanced version of Snowflake's virtual Standard Warehouse with next-generation hardware and additional enhancements to deliver 2.1x faster analytics performance. Snowflake also introduced Snowflake Adaptive Compute (now in private preview), a new compute service that lowers the burden of resource management by maximizing efficiency through automatic resource sizing and sharing. Warehouses created using Adaptive Compute, known as Adaptive Warehouses, accelerate performance for users without driving up costs, ultimately redefining data management in the evolving AI landscape. Snowflake Intelligence and Data Science Agent Deliver The Next Frontier of Data Agents for Enterprise AI and ML Snowflake announced Snowflake Intelligence (public preview soon), which enables technical and non-technical users alike to ask natural language questions and instantly uncover actionable insights from both structured tables and unstructured documents. Snowflake Intelligence is powered by state-of-the-art large language models from Anthropic and OpenAI, running inside the secure Snowflake perimeter, and is powered by Cortex Agents (public preview) under the hood — all delivered through an intuitive, no-code interface that helps provide transparency and explainability. Snowflake also unveiled Data Science Agent (private preview soon), an agentic companion that boosts data scientists' productivity by automating routine ML model development tasks. Data Science Agent uses Anthropic's Claude to break down problems associated with ML workflows into distinct steps, such as data analysis, data preparation, feature engineering, and training. Today, over 5,200 customers from companies like BlackRock, Luminate, and Penske Logistics are using Snowflake Cortex AI to transform their businesses. Snowflake Introduces Cortex AISQL and SnowConvert AI: Analytics Rebuilt for the AI Era Snowflake announced major innovations that expand on Snowflake Cortex AI, Snowflake's suite of enterprise-grade AI capabilities, empowering global organizations to modernize their data analytics for today's AI landscape. This includes SnowConvert AI, an agentic automation solution that accelerates migrations from legacy platforms to Snowflake. With SnowConvert AI, data professionals can modernize their data infrastructure faster, more cost-effectively, and with less manual effort. Once data lands in Snowflake, Cortex AISQL (now in public preview) then brings generative AI directly into customers' query engines, enabling teams to extract insights across multi-modal data and build flexible AI pipelines using SQL — all while providing best‑in‑class performance and cost efficiency. Snowflake Marketplace Adds Agentic Products and AI-Ready Data from Leading News, Research, and Market Data Providers Snowflake announced new agentic products on Snowflake Marketplace that accelerate agentic AI adoption across the enterprise. This includes Cortex Knowledge Extensions (generally available soon) on Snowflake Marketplace, which enables enterprises to enrich their AI apps and agents with proprietary unstructured data from third-party providers — all while allowing providers to protect their intellectual property and ensure proper attribution. Users can tap into a selection of business articles and content from The Associated Press, which will help users further enhance the usefulness of results in their AI systems. In addition, Snowflake unveiled sharing of Semantic Models (now in private preview), which allows users to easily integrate AI-ready structured data within their Snowflake Cortex AI apps and agents — both from internal teams or third-party providers like CARTO, CB Insights, Cotality powered by Bobsled, Deutsche Börse, IPinfo, and truestar.
Zawya
a day ago
- Zawya
M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care
Partnership will advance cancer diagnosis, inform treatment decisions, and enable real-time monitoring of disease progression in a more cost-effective and less invasive manner The launch is expected in the latter part of Q2 2025, following the completion of an initial validation study at Cleveland Clinic Abu Dhabi Abu Dhabi, United Arab Emirates: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS (Nasdaq: SOPH) to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing program will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care." Sameh El Fangary, Cluster President GCC, AstraZeneca, shared," At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.' R oss Muken, President of SOPHiA GENETICS, said: "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalize care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." About M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
Al Etihad
a day ago
- Al Etihad
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." Source: Aletihad - Abu Dhabi
